Stereotaxis is trading 5.21% down at $1.36 as broader risk-off conditions pressured U.S. equities on September 1, 2026.
- Renewed Middle East tensions lifted oil prices and bond yields as markets reassessed inflation and potential interest-rate increases.
- Reuters reported that higher borrowing costs and oil prices were weighing on stocks broadly; no new company-specific announcement was identified.
- Healthcare-sector strength provided limited support, leaving Stereotaxis moving against the trend as global macro sentiment drove the decline.